Bowling Portfolio Management LLC lessened its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 11.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,758 shares of the company’s stock after selling 1,973 shares during the period. Bowling Portfolio Management LLC owned about 0.06% of USANA Health Sciences worth $1,900,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. NEXT Financial Group Inc bought a new position in USANA Health Sciences during the third quarter worth about $121,000. CAPROCK Group Inc. bought a new position in USANA Health Sciences during the second quarter worth about $214,000. Amalgamated Bank bought a new position in USANA Health Sciences during the second quarter worth about $223,000. RNC Capital Management LLC bought a new position in USANA Health Sciences during the second quarter worth about $231,000. Finally, Nomura Holdings Inc. bought a new position in USANA Health Sciences during the second quarter worth about $250,000. Institutional investors and hedge funds own 51.48% of the company’s stock.
Separately, Pivotal Research reiterated a “hold” rating and set a $135.00 target price on shares of USANA Health Sciences in a research report on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $135.00.
USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, July 24th. The company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.25. USANA Health Sciences had a net margin of 7.16% and a return on equity of 29.50%. The company had revenue of $301.50 million during the quarter, compared to analyst estimates of $278.41 million. During the same period last year, the business earned $0.98 earnings per share. USANA Health Sciences’s revenue was up 17.3% compared to the same quarter last year. On average, sell-side analysts expect that USANA Health Sciences, Inc. will post 4.9 EPS for the current fiscal year.
In other news, Director Myron W. Wentz sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $119.89, for a total value of $3,596,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Global Ltd Gull bought 824 shares of the stock in a transaction that occurred on Saturday, December 8th. The stock was bought at an average cost of $70.70 per share, for a total transaction of $58,256.80. Following the completion of the purchase, the insider now directly owns 10,921,009 shares of the company’s stock, valued at $772,115,336.30. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 19,117 shares of company stock valued at $1,349,965 and sold 953,704 shares valued at $122,909,298. 53.20% of the stock is currently owned by company insiders.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Recommended Story: The Discount Rate – What You Need to Know
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.